Clinical Application Value of Deep Learning-Based "Opportunistic Screening" for Malignant Tumors on Routine Non-Contrast Chest-Abdomen-Pelvis CT
1 other identifier
observational
100,000
1 country
1
Brief Summary
This study aims to develop and validate a deep learning-based opportunistic multi-cancer screening system using routine non-contrast chest-abdomen-pelvis CT examinations, including CHANCE-Breast, CHANCE-Liver, CHANCE-Kidney, and CHANCE-Bladder, for the early detection of breast, liver, kidney, and bladder cancers. In addition, the study will assess a human-AI collaborative framework to determine its potential for improving cancer detection and reducing missed diagnoses in clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 5, 2026
CompletedFirst Posted
Study publicly available on registry
June 10, 2026
CompletedStudy Start
First participant enrolled
July 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2028
Study Completion
Last participant's last visit for all outcomes
July 1, 2028
June 10, 2026
June 1, 2026
2 years
June 5, 2026
June 5, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
diagnostic sensitivity
1.5 years
Study Arms (3)
Positive Group / Malignant Cohort
Negative Control Group I / Benign Cohort
Negative Control Group II / Healthy Cohort
Eligibility Criteria
Patients with a confirmed diagnosis of the target malignancy who received treatment.
You may qualify if:
- Patients with a confirmed diagnosis of the target malignancy who received treatment at our institution;
- Diagnostic-quality CT images without substantial metal or motion artifacts and with complete anatomical coverage of the target organ (breast, liver, kidney, or bladder);
- Availability of complete pre-treatment non-contrast CT imaging data.
You may not qualify if:
- Non-diagnostic image quality;
- Absence of a definitive reference-standard diagnosis;
- Incomplete clinical or imaging data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Lian Yanglead
Study Sites (1)
Union Hospital,Tongji Medical College,Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China
MeSH Terms
Conditions
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
June 5, 2026
First Posted
June 10, 2026
Study Start (Estimated)
July 1, 2026
Primary Completion (Estimated)
July 1, 2028
Study Completion (Estimated)
July 1, 2028
Last Updated
June 10, 2026
Record last verified: 2026-06